Calamos Advisors’s Integrated Wellness Acquisition Corp Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant WEL.U Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-308,270
Closed -$3.14M 1601
2022
Q3
$3.14M Hold
308,270
0.01% 787
2022
Q2
$3.1M Hold
308,270
0.01% 826
2022
Q1
$3.13M Hold
308,270
0.01% 819
2021
Q4
$3.11M Buy
+308,270
New +$3.11M 0.01% 807

Other funds holding WEL.U

Calamos Advisors's WEL.U Position: Q4 2022 in Review

Calamos Advisors sold out of Integrated Wellness Acquisition Corp Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant (WEL.U) in Q4 2022, closing a stake of 308,270 shares — an estimated $3.14M sold.

Calamos Advisors first reported a position in WEL.U in Q4 2021 and held it in 4 quarters. The position peaked at $3.14M in Q3 2022. 5 funds tracked by Wall St. Rank hold WEL.U as of Q4 2022.

  • Calamos Advisors reported no remaining Integrated Wellness Acquisition Corp Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant position as of Q4 2022 after selling out during the quarter.
  • Calamos Advisors sold 308,270 Integrated Wellness Acquisition Corp Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant shares in Q4 2022, an estimated $3.14M.
  • Calamos Advisors first reported a position in Integrated Wellness Acquisition Corp Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant in Q4 2021 and held it in 4 quarters.
  • Calamos Advisors's Integrated Wellness Acquisition Corp Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant position peaked at $3.14M in Q3 2022.
  • 5 funds tracked by Wall St. Rank held Integrated Wellness Acquisition Corp Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant as of Q4 2022.

Based on Calamos Advisors's 13F filing for Q4 2022, filed 26 Jan 2023.